GT Biopharma (FRA:OXIA) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:OXIA GT Biopharma Inc FRA:OXIA
28 GF Score
Price €4.77
! 1 Warning Sign
View Full Analysis

What is GT Biopharma Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

FRA:OXIA
28GF Score
GT Biopharma Inc FRA:OXIA
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GT Biopharma Business Description

Other Exchanges GTBP:USA
Address 315 Montgomery Street, 10th Floor, San Francisco, CA, USA, 94104
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.
28GF Score

Get the complete analysis for FRA:OXIA

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.77
Price